Treated effect of silymarin on vascular function of aged rats: Dependant on nitric oxide pathway

References

• Ahmadi-Ashtiani H, Allameh A, Rastegar H, et al. (2012). Inhibition of cyclooxygenase-2 and inducible nitric oxide synthase by silymarin in proliferating mesenchymal stem cells: Comparison with glutathione modifiers. J Nat Med 66:85–94
   PubMed Web of Science ®Google Scholar
• Cau SB, Carneiro FS, Tostes RC. (2012). Differential modulation of nitric oxide synthases in aging: Therapeutic opportunities. Front Physiol 3:218 . doi: 10.3389/fphys.2012.00218
   PubMed Web of Science ®Google Scholar
• Cheung CW, Gibbons N, Johnson DW, Nicol DL. (2010). Silibinin – a promising new treatment for cancer. Anticancer Agents Med Chem 10:186–95
   PubMed Web of Science ®Google Scholar
• Chlopcikova S, Psotova J, Miketova P, Simanek V. (2004). Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res 18:107–10
   PubMed Web of Science ®Google Scholar
• Demirci B, McKeown PP, Bayraktutan U. (2005). Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects. J Hypertens 23:2219–27
   PubMed Web of Science ®Google Scholar
• Demirci B, McKeown PP, Bayraktutan U. (2008). The bimodal regulation of vascular function by superoxide anion: Role of endothelium. BMB Rep 41:223–9
   PubMed Web of Science ®Google Scholar
• El-Shitany NA, El-Haggar S, El-desoky K. (2008). Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol 46:2422–8
   PubMed Web of Science ®Google Scholar
• Feher J, Lengyel G. (2012). Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol 13:210–17
   PubMed Web of Science ®Google Scholar
• Gabrielova E, Jaburek M, Gazak R, et al. (2010). Dehydrosilybin attenuates the production of ROS in rat cardiomyocyte mitochondria with an uncoupler-like mechanism. J Bioenerg Biomembr 42:499–509
   Google Scholar
• Kang JS, Park SK, Yang KH, Kim HM. (2003). Silymarin inhibits TNF-alpha-induced expression of adhesion molecules in human umbilical vein endothelial cells. FEBS Lett 550:89–93
   Google Scholar
• Karaki H, Ozaki H, Hori M, et al. (1997). Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 49:157–230
   PubMed Web of Science ®Google Scholar
• Kroll DJ, Shaw HS, Oberlies NH. (2007). Milk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6:110–19
   PubMed Web of Science ®Google Scholar
• Pliskova M, Vondracek J, Kren V, et al. (2005). Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 215:80–9
   PubMed Web of Science ®Google Scholar
• Rao PR, Viswanath RK. (2007). Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Exp Clin Cardiol 12:179–87
   PubMedGoogle Scholar
• Tugrul I, Demirci B, Demir O, et al. (2011). The effect of Hypericum perforatum on isolated rat aorta. Pharm Biol 49:879–83
   PubMed Web of Science ®Google Scholar
• Tyagi A, Agarwal C, Dwyer-Nield LD, et al. (2012). Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog 51:832–42
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Kaley G, de CR, et al. (2010). Mechanisms of vascular aging: New perspectives. J Gerontol A Biol Sci Med Sci 65:1028–41
   PubMed Web of Science ®Google Scholar
• Volti GL, Salomone S, Sorrenti V, et al. (2011). Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. Cardiovascular Diabetol 10:1–8
   Google Scholar
• Wang YK, Hong YJ, Huang ZQ. (2005). Protective effects of silybin on human umbilical vein endothelial cell injury induced by H2O2 in vitro. Vascul Pharmacol 43:198–206
   PubMed Web of Science ®Google Scholar
• Wong SL, Wong WT, Tian XY, et al. (2010a). Prostaglandins in action indispensable roles of cyclooxygenase-1 and -2 in endothelium-dependent contractions. Adv Pharmacol 60:61–83
   PubMedGoogle Scholar
• Wong WT, Wong SL, Tian XY, Huang Y. (2010b). Endothelial dysfunction: The common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 55:300–7
   PubMed Web of Science ®Google Scholar
• Zhou B, Wu LJ, Tashiro S, et al. (2006). Silibinin protects rat cardiac myocyte from isoproterenol-induced DNA damage independent on regulation of cell cycle. Biol Pharm Bull 29:1900–5
   PubMed Web of Science ®Google Scholar